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SJL mice are highly susceptible to experimental autoimmune en-
cephalomyelitis (EAE) induced with myelin proteolipid protein
(PLP) peptide 139–151, whereas H-2 congenic B10.S mice are
resistant. Immunodominance and susceptibility to EAE are associ-
ated with a high precursor frequency of PLP 139–151-specific T cells
in the naı¨ve repertoire of SJL mice. To understand the mechanism
of EAE resistance in B10.S mice, we determined the precursor
frequency of PLP 139–151-reactive T cells in both strains by using
IAsPLP 139–151 tetramers. SJL and B10.S mice had similar frequen-
cies of tetramer-reactive T cells in the naı¨ve peripheral repertoire.
However, in SJL mice, the majority of PLP 139–151 tetramer-
positive cells were in the CD4CD25 population, whereas there
were more tetramer-positive cells in the CD4CD25 population of
B10.S mice. Depletion of CD4CD25 cells in vivo facilitated the
expansion of PLP 139–151-reactive cells with production of T
helper 1 cytokines in EAE-resistant B10.S mice. Furthermore, anti-
CD25 Ab treatment before immunization resulted in EAE induction
in these otherwise resistant mice. These data indicate an important
role for autoantigen-specific CD4CD25 cells in genetic resistance
to autoimmunity.
S tudies in various models of experimental autoimmune en-cephalomyelitis (EAE) have provided new insights into
autoimmune disease mechanisms. In SJL mice, we and others
have shown that proteolipid protein (PLP) 139–151 is the
immunodominant encephalitogenic PLP epitope and that it
induces severe EAE (1–3). In contrast, B10.S mice are highly
resistant, even though both strains carry the H-2s MHC mole-
cules (3), suggesting that differences in non-MHC genes con-
tribute to susceptibility and resistance to EAE. By using crosses
between SJL and B10.S mice, we and others have identified
multiple loci that contribute to disease susceptibility (3–6), but
the actual genes and cellular mechanisms determining suscep-
tibility have not been elucidated.
There is now considerable evidence that CD4CD25 T cells
play a critical role in the regulation of autoimmune diseases
(7–9). They constitutively express Forkhead box P3 (10, 11).
Emerging evidence suggests that CD4CD25 cells are gener-
ated in the thymus by a high-affinity interaction of the T cell
receptor (TCR) with self-peptides bound to MHC II molecules
rendering these self-reactive cells anergic (12–14). However, the
antigen (Ag)-binding specificity of the TCR of regulatory
CD4CD25 cells that suppress autoimmunity is not known. By
using IAsPLP 139–151 tetramers, we show here that EAE-
resistant, B10.S mice possess significantly greater proportions of
PLP 139–151-reactive CD4CD25 T cells in their periphery
when compared with EAE-susceptible, SJL mice. CD4CD25
cells suppressed the expansion of PLP 139–151-responsive
CD4CD25 cells in naı¨ve B10.S mice. Anti-CD25 Ab treatment
of B10.S mice resulted in an increase in PLP 139–151-specific T
cell proliferation with significant IFN- production. Further-
more, depletion of CD4CD25 cells in vivo with an anti-CD25
Ab resulted in a higher incidence of EAE in normally resistant
B10.S mice. These results point to a pivotal role for Ag-specific
CD4CD25 T cells in the regulation of susceptibility to EAE.
Materials and Methods
Mice. SJL mice were procured from The Jackson Laboratory
(Bar Harbor, ME), and B10.S mice were obtained from the
McLaughlin Research Institute (Great Falls, MT). The mice
were maintained according to the animal protocol guidelines of
Harvard Medical School.
Peptide Synthesis, Immunization Protocols, and Delayed Type Hyper-
sensitivity (DTH). PLP 139–151 (HSLGKWLGHPDKF), Theiler’s
murine encephalomyelitis virus (TMEV) VP2 70 – 86
(WTTSQEAFSHIRIPLP), ovalbumin (OVA) 323–329
(ISQAVHAAHAEINEAGR), and neuraminidase (NASE)
101–120 (EALVRQGLAKVAYVYKPNNT) were synthesized
on 9-fluorenylmethyloxycarbonyl chemistry (QCB, BioSource,
Hopkinton, MA). For immunizations, 100–150 g of each
peptide emulsified in complete Freund’s adjuvant was adminis-
tered s.c. DTH responses were measured 7 days after immuni-
zation by injecting 100 g of PLP 139–151 into the right footpad.
Twenty-four hours later, DTH responses were assessed by
measuring the thickness of the hind foot with a micrometer
(Mitutoyo, Tokyo) and comparing it with the thickness of the
uninjected left hind foot.
T Cell Proliferation. Single-cell suspensions were obtained from
spleens and lymph nodes (LN) of naı¨ve SJL and B10.S mice, and
CD4CD25 and CD4CD25 subsets were fractionated by
magnetic separation using LS columns (Miltenyi Biotec, Auburn
CA). For proliferation assays, 1.5 to 2.0  106 cells per ml
CD4CD25 or CD4CD25 cells or both were cultured with
anti-CD3 Ab (0–1 gml) in HL-1 medium (BioWhittaker) for
2 days or PLP 139–151 (0–150 gml) for 3 days in the presence
of antigen-presenting cells (APC). Sixteen hours after pulsing
with 1 Ci of [3H]thymidine (1 Ci  37 GBq), proliferation was
measured as cpm by using a Wallac liquid scintillation counter
(PerkinElmer). CD3T cells from draining LN were enriched by
negative selection (R & D Systems). To determine recall re-
sponses to PLP 139–151 in B10.S mice depleted of CD25 cells,
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400 g of anti-CD25 Ab (clone PC61, BioExpress, West Leba-
non, NH) and its isotype control (rat IgG, ICN Biomedicals,
Aurora, OH) were administered i.p. on days 5 and 3 into 4-
to 8-week-old mice. The mice were immunized with 150 g of
PLP 139–151 in complete Freund’s adjuvant on day 0. Ten days
later, recall responses of CD3 T cells to PLP 139–151 were
tested, as described above.
IAs Tetramer Staining. IAs tetramers for PLP 139–151 and TMEV
70–86 were generated as described in ref. 15. TMEV tetramers
were used as negative controls. T cells enriched from LN of naı¨ve
SJL and B10.S mice were treated with neuraminidase (0.7
unitsml) in serum-free medium (DMEM, BioWhittaker) at a
density of 1 107 cells per ml for 1 h at 37°C. After washing, cells
were incubated with the tetramers (30 gml) for 3–4 h at 37°C
in DMEM containing IL-2 (pH 8.0), followed by staining with
anti-CD4-APC (clone RM4.5), anti-CD25-FITC (clone 7D4),
and 7-amino-actinomycin D (7-AAD) (all three from Pharmin-
gen). Cells were acquired by using the FACSort flow cytometer
(Becton Dickinson), and tetramer-positive cells were deter-
mined in live CD4 or CD25 populations after gating the dead
(7-AAD) cells by using the programs CELLQUEST (Becton
Dickinson) and FLOWJO (Tree Star, Ashland, OR).
Cytokine Measurement. To determine the frequency of cytokine-
producing cells, LN cells (LNC) from SJL or B10.S mice
immunized with PLP 139–151 with or without anti-CD25
control Ab treatment were restimulated twice with PLP 139–151
(20 gml). Viable cells then were stimulated with anti-TCR Ab
(clone H57597, 2.5gml) and anti-CD28 (clone 37.51, 4gml)
and 2 mM monensin (GolgiStop, Pharmingen) for 4–6 h at 37°C.
After staining with anti-CD4 (clone RM 4.5-APC) and 7-AAD,
the cells were stained with cytokine Ab as recommended by the
manufacturer (Pharmingen). Supernatants from the above cul-
tures were tested for IL-2, IL-4, IL-10, and IFN- as described
in ref. 16.
Induction of EAE. Eight- to twelve-week-old mice were immunized
s.c. in the flanks with an emulsion containing PLP 139–151 and
Mycobacterium tuberculosis, H37Ra extract (4 mgml) (Difco) in
complete Freund’s adjuvant. To determine the effect of anti-
CD25 Ab treatment on the development of EAE, 4- to 8-week-
old B10.S mice of either sex were treated with anti-CD25 Ab
(clone PC61) or rat IgG isotype control twice on days5 and3
before inducing EAE. Pertussis toxin was administered (100 ng
per mouse) i.p. on the day of immunization and day 2 after
immunization. The mice were observed for signs of EAE for up
to 4 weeks and scored as described in refs. 2 and 3.
Histopathology. Mice were killed when they reached a score of 4
or higher or when they began to recover from disease as
indicated by a lack of further increase in clinical score. Brains
and spinal cords from the mice were fixed in 10% phosphate-
buffered formalin. Histological disease was evaluated by count-
ing inflammatory foci in meninges and parenchyma as described
in ref. 17.
Statistics. Comparisons of the differences in immune responses
(proliferation, DTH, and IFN- production) and numbers of IAs
tetramer-positive cells in SJL and B10.S mice were made by using
Student’s t test. The incidence of PLP 139–151-induced EAE in
SJL and B10.S mice was analyzed by Fisher’s exact test. P 0.05
was considered significant.
Results
B10.S Mice Are Unresponsive to the Encephalitogenic PLP 139–151
Peptide. After immunization with PLP 139–151, the disease
incidence and mean clinical scores in a cohort of B10.S mice were
significantly lower than in SJL mice (P  0.0001 for both) (see
Table 2, which is published as supporting information on the
PNAS web site). Thus, resistance to PLP 139–151-induced EAE
in B10.S mice likely was influenced by non-MHC genes. To
determine whether B10.S mice have a generalized defect in the
expansion of T cells that recognize self or nonself Ags, B10.S
mice were immunized with self (PLP 139–151) and foreign Ags
(OVA), and recall responses to PLP 139–151, OVA, and purified
protein derivative were tested. As shown in Table 2, proliferation
and IFN- production in response to PLP 139–151 were signif-
icantly lower in B10.S mice compared with SJL mice (P 0.0001
and P  0.001, respectively). Correspondingly, the DTH re-
sponse to PLP 139–151 was substantially lower in B10.S mice
(P  0.02). By contrast, LNC from B10.S and SJL mice re-
sponded comparably to foreign Ags (purified protein derivative
and OVA) as indicated by the production of IFN-, suggesting
that the defect in the T cell response in B10.S mice was restricted
largely to the autoantigen. These results were verified further by
using class IIIAs tetramers specific for PLP 139–151 or TMEV
70–86 peptides. In cultures derived from SJL mice immunized
with PLP 139–151, there were nearly 3-fold more PLP 139–151
tetramer-reactive CD4 cells than there were in cells from B10.S
mice (2.10% vs. 0.83%) (Fig. 1a). By contrast, in cultures from
TMEV 70–86-immunized mice, the frequencies of TMEV
70–86 tetramer-reactive cells were similar in SJL and B10.S
mice, although the frequency in B10.S mice was slightly lower
(0.79% vs. 0.56%) (Fig. 1a). Recall responses to these peptides
followed a similar trend (see Fig. 6, which is published as
supporting information on the PNAS web site). The frequency
Fig. 1. B10.S mice have a diminished recall response to PLP 139–151. (a)
Tetramer staining. LNC from SJL and B10.S mice immunized with PLP 139–151
or TMEV 70–86 peptide were restimulated with the corresponding peptides,
and percentages of IAs tetramer-positive cells were determined in the viable
(7-AAD) CD4 populations. (b) Intracellular cytokine staining. LNC from SJL
and B10.S mice immunized with PLP 139–151 were restimulated with PLP
139–151. After 3 days, frequencies of IL-2- and IFN--secreting cells were
determined by flow cytometry. A representative experiment from three or
four individual experiments involving two or three mice per group is shown in
each plot.









of cytokine-secreting CD4 cells in cultures stimulated with PLP
139–151 revealed comparable numbers of IL-2-producing cells
in SJL and B10.S mice, but the frequency of IFN--secreting cells
was 4-fold higher in SJL mice (Fig. 1b).
Naı¨ve SJL and B10.S Mice Differ in the Frequency of PLP 139–151-
Reactive T Cells in CD4CD25 and CD4CD25 Subsets. The fre-
quency of PLP 139–151-tetramer positive CD4 cells in the
naı¨ve repertoire of SJL and B10.S mice varied greatly among
individual mice (0.02–0.81%), but the average for large num-
bers of SJL and B10.S mice was 0.2% (Fig. 2a). This
frequency (40 PLP-reactive cells in 20,000 CD4 cells) is
significantly higher than that determined by limiting dilution
assay (1 in 20,000) (18) and may ref lect enhanced sensitivity
of detection with tetramers that does not depend on in vitro
expansion of Ag-specific T cells. Reactivity to the TMEV
70–86 tetramer was present in both strains but at significantly
lower frequencies (average  0.07% and 0.09% in SJL and
B10.S mice, respectively) than observed for PLP 139–151
tetramers. Therefore, these data indicate that differences in T
cell expansion between SJL and B10.S mice to PLP 139–151
after immunization cannot be explained simply by a difference
in precursor frequency in their naı¨ve repertoires.
We next determined whether there are differences in IAsPLP
139–151 tetramer-reactive T cells in the CD4CD25and
CD4CD25 compartments of these mice. We found that in SJL
mice, the majority of PLP 139–151 tetramer-reactive cells were
in the CD4CD25 subset but that in the B10.S mice, the PLP
139–151 tetramer-reactive cells were present in nearly equal
proportions in the CD4CD25 and CD4CD25 populations
(Fig. 2b). Furthermore, analysis of ratios of CD4CD25 to
CD4CD25 in the PLP 139–151 and TMEV 70–86 tetramer-
reactive T cells demonstrated a significantly higher proportion of
PLP 139–151 tetramer-reactive cells in the CD4CD25 cell
subset in B10.S mice compared with SJL mice (Fig. 2c). There
were no differences in the TMEV 70–86 tetramer-reactive
populations. Because CD4CD25 cells include naturally oc-
curring regulatory cell populations, this observation raised the
possibility that PLP tetramer-reactive CD4CD25 T cells may
influence susceptibility to EAE in B10.S mice.
CD4CD25 Cells Are Functional and Their Suppressive Effect Is
Ag-Specific. To determine whether CD4CD25 cells in SJL
and B10.S mice are equally capable of regulating T cell
responses, we first tested their ability to proliferate in the
presence of the polyclonal activator, anti-CD3 Ab. As shown
in Fig. 3a, CD4CD25 cells from both SJL and B10.S mice did
not respond to anti-CD3 Ab stimulation, whereas
CD4CD25 cells showed significant proliferative responses
to the anti-CD3 Ab. In a coculture of the two populations,
CD4CD25 cells inhibited the proliferative responses of
CD4CD25 cells 5- to 8-fold. Therefore, there is no global
defect in the functional activity of CD4CD25 cells to
mediate their suppressive functions in either SJL or B10.S
strains. Next, we compared the suppressive activity of
CD4CD25 cells with the specific self-Ag PLP 139–151. As
expected, CD4CD25 cells from either SJL or B10.S mice did
not respond to PLP 139–151, and CD4CD25 cells showed a
strong proliferative response to PLP 139–151 (Fig. 3b). How-
ever, when CD4CD25 cells were cocultured with
CD4CD25 cells, the proliferative response of the
CD4CD25 cells to PLP 139–151 was inhibited (3- to 4-fold)
in B10.S mice. In contrast, the CD4CD25 cells derived from
the SJL mice did not inhibit responses to PLP 139–151 as
effectively as in the B10.S mice (Fig. 3b). These data suggest
that CD4CD25 cells may play a role in preventing expansion
of PLP 139–151-specific T cells in B10.S mice. However, there
was no inherent defect in the PLP-reactive effector cells in SJL
mice, because CD4CD25 T cells from B10.S mice could
inhibit the expansion of CD4CD25 T cells from SJL mice as
efficiently and effectively as they inhibited CD4CD25 T
cells from B10.S mice (data not shown). The efficient inhibi-
tion by B10.S derived CD4CD25 T cells may be attributed
to a higher frequency of PLP 139–151-reactive, CD4CD25
T cells in B10.S than in SJL mice (Fig. 2 b and c).
Fig. 2. Naı¨ve B10.S mice have greater proportions of PLP 139–151-reactive
CD4CD25 T cells in their periphery than naı¨ve SJL mice. (a) CD3 T cells from
naı¨ve SJL and B10.S mice were stained with IAs tetramers (PLP 139–151 and
TMEV 70–86) after treatment with neuraminidase, and the tetramer-positive
cells were enumerated in the live CD4 population. Horizontal bars indicate
the average frequency of tetramer-positive CD4 cells. (b) CD3 T cells from
naı¨ve SJL and B10.S mice were incubated with IAs tetramers (PLP 139–151 or
TMEV 70–86) after neuraminidase treatment, and frequencies of tetramer-
positive cells were determined in the live CD4 population in relation to the
CD25 marker. (c) The relative precursor frequencies of PLP 139–151 tetramer-
positive cells are expressed as the ratio of tetramer-positive cells in the
CD4CD25 compartment to those in the CD4CD25 negative compartment
(n  4 per group).
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Depletion of CD25 Cells in Vivo Enhances PLP 139–151-Specific T Cell
Responses in B10.S Mice. We depleted CD25 cells in B10.S mice
before immunization with PLP 139–151 and tested recall re-
sponses to PLP 139–151 or NASE 101–120 (control) after 10
days. T cells from anti-CD25 Ab-treated mice responded more
vigorously to PLP 139–151 than T cells from the control
IgG-treated group (Fig. 4a). In the anti-CD25 Ab-treated group,
there was also an increase in the basal proliferation of cells, i.e.,
without Ag, which may reflect a general lack of regulatory
control mediated by CD4CD25 cells. The response to PLP
139–151 was specific because it followed a typical dose-response,
and there was no response to the control peptide (Fig. 4a). By
using IAs tetramers, we found that the PLP 139–151-reactive
cells were present at a frequency 3-fold higher in the anti-
CD25 treated group than in the IgG control Ab-treated group
(Fig. 4b).
T Cells from Anti-CD25-Treated B10.S Mice Produce Significant
Amounts of IFN-. One factor involved in EAE resistance in B10.S
mice is that immunization does not induce myelin basic protein
(MBP)-specific IFN- production (19). Because B10.S mice
possess significant numbers of PLP-reactive CD4CD25 cells,
we hypothesized that they may keep the expansion of pathogenic
effector cells that are capable of producing IFN- in check. In
both anti-CD25 Ab- and isotype control-treated mice, there were
cells capable of producing all of the cytokines tested (IL-2, IL-5,
IL-10, and IFN-). However, in contrast to the isotype control-
treated group, the frequency of IL-10-secreting cells was reduced
and the frequency of IFN--producing cells was increased in
anti-CD25 Ab-treated mice (Fig. 5a). There was also an increase
in the frequency of IL-2-producing cells in the anti-CD25-
treated cultures. These profiles were verified by cytokine ELISA,
which revealed that in the cultures from B10.S mice treated with
anti-CD25 Ab, there was a significant increase in IFN- pro-
duction with a concomitant decrease in IL-10 production (Fig.
5b). The data thus suggest that the anti-CD25 Ab treatment
resulted in the expansion of PLP 139–151-reactive cells produc-
ing T helper 1 (Th1) cytokines after immunization with PLP
139–151.
Depletion of CD25 Cells in Vivo Induces EAE in B10.S Mice. Because
depletion of CD25 cells in vivo altered proliferative responses
and IFN- production of PLP 139–151-reactive T cells, we
determined whether anti-CD25 Ab treatment made B10.S mice
susceptible to EAE. After depleting CD25 cells with anti-CD25
Ab, the mice were immunized with PLP 139–151 in complete
Freund’s adjuvant . As shown in Table 1, B10.S mice treated with
control Ab did not develop clinical EAE, whereas about one-
third of the CD25 Ab-treated mice developed clinical EAE
(P 0.0015). Inflammatory foci were detected in both meninges
and parenchyma in anti-CD25 Ab-treated mice, whereas none of
the control Ab-treated mice showed any histological disease
(Table 1).
Fig. 3. CD4CD25 cells in SJL and B10.S mice are functional. (a) CD4CD25
and CD4CD25 fractions were enriched from naı¨ve SJL and B10.S mice. The
different populations, either alone or together, were stimulated with anti-
CD3 Ab in the presence of APC, and proliferative responses were measured as
cpm. (b) CD4CD25and CD4CD25populations as inawere stimulated with
PLP 139–151 (150 gml) in the presence of APC, and proliferative responses
were measured. A representative experiment from three to five individual
experiments is shown in each graph.
Fig. 4. Depletion of CD25 cells in vivo enhances PLP 139–151-specific T cell
responses in B10.S mice. (a) Proliferation. CD3 T cells from PLP 139–151-
immunized B10.S mice that had been treated with anti-CD25 Ab or rat IgG
control were restimulated with PLP 139–151, and proliferative responses were
measured. (b) IAs tetramer staining. CD3 T cells from PLP 139 –151-
immunized B10.S mice that were pretreated with anti-CD25 Ab or rat IgG were
restimulated with PLP 139–151 for 4 days. The percentages of IAs tetramer (PLP
139–151, TMEV 70–86)-positive cells were determined in the viable (7-AAD)
CD4 subset. A representative experiment from five individual experiments
involving two mice per group is shown.










In this study, we describe the cellular basis for resistance to EAE
in B10.S mice after immunization with PLP 139–151. Both SJL
and B10.S mice possess the same MHC haplotype H-2s, yet they
differ in their susceptibility to EAE, suggesting that background
genes play a crucial role in disease resistance in B10.S mice. A
lack of expansion and production of IFN- after immunization
with PLP 139–151 led us to investigate the cellular mechanisms
that contribute to EAE resistance in this strain.
After immunization, B10.S mice showed a blunted T cell
response to the self-Ag, PLP 139–151 but not to foreign Ags. We
speculated that there might be differences in the frequency of
PLP 139–151-reactive T cells in the periphery of naı¨ve SJL and
B10.S mice, but direct measurement with PLP 139–151-I-As
tetramers showed that this was not the case. Expanded popula-
tions of autoreactive T cells have been demonstrated for two
other autoantigens, i.e., pancreatic Ag-specific CD4 cells in
nonobese diabetic mice that are recognized by the BDCIAg7
tetramer (20, 21) and the human CD8 cells recognized by class
I tetramers that react with the melanocyte-differentiating Ag,
MELAN-A, in healthy HLA-A2 individuals (22). How these
autoreactive T cells are generated and maintained in the pe-
ripheral repertoire and whether they are critical for the devel-
opment of autoimmune disease has not been determined.
When we analyzed IAsPLP 139–151 tetramer-reactive cells in
relation to CD25, the fraction of PLP 139–151 tetramer-reactive,
CD4CD25 cells was strikingly higher in B10.S than in SJL
mice (Fig. 2 b and c). This finding led us to question whether the
difference in the fraction of regulatory PLP 139–151-specific,
TCR-bearing CD4 cells could explain partly the differences in
the expansion of PLP 139–151-specific T cells, IFN- produc-
tion, and disease susceptibility between the two strains.
It is now widely accepted that CD4CD25 cells can play a
critical role in the development of autoimmune disease (7–9).
CD4CD25 cells have been found to inhibit the expansion of
CD4CD25 cells in vitro in coculture systems by using poly-
clonal activators such as anti-CD3 and Con-A (9, 23, 24).
However, it was not known whether the suppressive function of
CD4CD25 cells is Ag-specific. Here, we demonstrate that in
naı¨ve animals, CD4CD25 cells act as natural regulatory cells
in that they prevent expansion of PLP 139–151-reactive
CD4CD25 in an Ag-specific manner (Fig. 3b). This inhibitory
function was more pronounced in EAE-resistant B10.S mice
than in EAE-susceptible SJL mice, and these differences were
reflected in the numbers of Ag-reactive T cells in CD4CD25
and CD4CD25 compartments (Fig. 2 b and c). By depleting
CD25 cells in B10.S mice and immunizing with PLP 139–151,
we confirmed that both Ag-specific proliferation (Fig. 4) and
IFN- production (Fig. 5) were increased significantly. Consis-
tent with these results, approximately one-third of the mice
treated with anti-CD25 Ab developed clinical and histological
evidence of EAE. Because not all of the mice developed EAE,
the EAE resistance of B10.S mice may not lie entirely in the
CD25 compartment. Taken together, however, the data suggest
that the CD4CD25 T cells specific to PLP 139–151 exist in the
peripheral naı¨ve repertoire and that they are functional.
Upon immunization with self-myelin Ags, B10.S mice prefer-
entially produce more IL-4 and IL-10, prototypical Th2 cyto-
kines, than SJL mice (25). The deviation of the immune response
toward a Th1 phenotype as a consequence of CD25 cell
depletion that we describe here suggests that PLP 139–151-
reactive CD4CD25 T cells are the source of Th2 cytokines,
specifically IL-10, or promote the induction of IL-10 by other
Fig. 5. Anti-CD25 Ab treatment alters cytokine production toward a Th1
phenotype. (a) Intracellular staining. LNC from PLP 139–151-immunized B10.S
mice that were pretreated with anti-CD25 or rat IgG Ab were restimulated
twice with PLP 139–151. Viable lymphoblasts were restimulated with anti-TCR
and anti-CD28 Ab for 4–6 h. After staining with anti-CD4 Ab and 7-AAD, the
frequency of IL-2-, IL-4-, IL-5-, IL-10-, and IFN--secreting cells was determined
in the live (7-AAD) CD4 subset by using flow cytometry. A representative
sample from six individual experiments is shown.*, Isotype control for IL-2 and
IL-10; **, Isotype control for IL-4 and IL-5 and IFN-. (b) Cytokine ELISA.
Supernatants from the above cultures were analyzed by ELISA for production
of IL-2, IL-4, IL-10, and IFN- . Each bar represents mean  SEM values for a
group of experiments (anti-CD25 Ab, n  5; rat IgG, n  6).
Table 1. Clinical and histological evaluation of EAE induced by PLP 139–151 in B10.S mice treated with anti-CD25




no. of inflammatory lesions
Incidence‡ (%) Mean day of onset Mean maximum score Meninges Parenchyma Total
Anti-CD25 Ab 932 (28.1) 13.8  1.4 2.2  0.6 44.1  14.0 42.6  17.6 86.9  31.1
Rat IgG control 034 (0) 0 0 0 0 0
Numbers are mean  SEM
*B10.S mice were treated with anti-CD25 or rat IgG Ab on days 5 and 3 prior to immunization with PLP 139–151 in CFA, and the disease
was scored as described in Materials and Methods and compared between the two groups (P  0.0015).
†n  9 for the anti-CD25 Ab group, and n  27 for the rat IgG control group.
‡Represents the mice that showed both clinical and histological EAE.
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cells under normal conditions. By contrast, CD4CD25 cells
appear to secrete IFN- preferentially. Thus, CD4CD25 cells
may control pathogenic T cells by direct inhibition or by inducing
production of antiinflammatory cytokines such as IL-10 and
control expansion of pathogenic effector T cells. Lack of such a
control would allow expansion of pathogenic T cells, i.e., IFN-
-producing CD4CD25 T cells, to the threshold required to
induce the disease. Nonetheless, because not all of the mice
treated with anti-CD25 Ab developed EAE, other factors such
as environmental effects, efficiency of CD25 cell depletion, and
effects of background genes may have influenced disease sus-
ceptibility. Indeed, IL-4 and IL-10 were still present in mice
depleted of CD25 cells. This observation implies that even in
the mice made vulnerable to EAE by CD25 cell depletion, there
is a certain amount of regulatory control mediated by the
antiinflammatory properties of IL-4 and IL-10 that prevented all
of the mice treated with anti-CD25 Ab from developing the
disease. It is known that resistance of B10.S mice to MBP-
induced EAE is secondary to an Ag-specific defect in the
generation of Th1 cells that produce IFN- and that this defect
can be restored by supplementing the MBP-reactive T cells with
IL-12 (19). In addition, B10.S mice have a defect in their capacity
to up-regulate the IL-12R 2 subunit, which results from a
failure of MBP-specific T cells to up-regulate CD40 ligand
expression and to induce IL-12 production (26). Taken together,
resistance to EAE in B10.S mice appears to be mediated by
multiple factors. Here, we provide evidence that CD4CD25
cells may be one of the critical components that confers resis-
tance to PLP 139–151-induced disease.
We have demonstrated that self-Ag reactive CD4CD25
cells exist in the periphery, but it is not known how they are
generated. Generation of CD4CD25 cells requires high-
avidity interactions of their TCR with self-peptide MHC com-
plexes in the thymus, but the extent of their interactions must be
low enough to avoid deletion (13). By real-time quantitative PCR
analysis, we observed that B10.S mice express larger amounts of
PLP mRNA in the thymus than SJL mice, although these strains
have comparable levels of PLP expression in the brain (data not
shown). Given that SJL mice have fewer PLP 139–151-reactive
CD4CD25 cells in their naı¨ve periphery than B10.S mice,
higher thymic PLP expression in B10.S mice may favor the
generation of PLP-specific CD4CD25 cells. This question can
be investigated directly by testing the frequency of CD4CD25
T cells in PLP-deficient B10.S mice, once they become available.
In summary, we show here that the naı¨ve repertoire of both
B10.S and SJL mice contain T cells that recognize PLP139–151
at similar frequencies and that upon immunization, EAE-
resistant B10.S mice fail to mount a sustained proliferative
response. This blunted response in B10.S mice is at least in part
due to a higher relative frequency of PLP 139–151 tetramer-
reactive CD4CD25 cells in their peripheral repertoire. De-
pletion of CD25 cells in vivo conferred EAE susceptibility to
B10.S mice. Our data provide evidence that naturally occurring
PLP 139–151-specific, tetramer-reactive CD4CD25 regula-
tory cells in part control genetic susceptibility and resistance to
EAE.
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